Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry
dc.creator | Malizos K., Sarma J., Seaton R.A., Militz M., Menichetti F., Riccio G., Gaudias J., Trostmann U., Pathan R., Hamed K. | en |
dc.date.accessioned | 2023-01-31T08:56:19Z | |
dc.date.available | 2023-01-31T08:56:19Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1007/s10096-015-2515-6 | |
dc.identifier.issn | 09349723 | |
dc.identifier.uri | http://hdl.handle.net/11615/76197 | |
dc.description.abstract | Osteomyelitis is a serious infection predominantly caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Orthopaedic device-related infections are complex and require a careful combination of surgical intervention and antimicrobial therapy. Daptomycin, a cyclic lipopeptide, effectively penetrates soft tissue and bone and demonstrates rapid concentration-dependent bactericidal activity against Gram-positive pathogens. This retrospective, non-interventional study evaluated clinical outcomes in patients with osteomyelitis or orthopaedic device infections treated with daptomycin from the European Cubicin® Outcomes Registry and Experience (EU-CORESM) study. Patients were treated between January 2006 and April 2012, with follow-up to 2014. Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Of 6,075 patients enrolled, 638 (median age, 63.5 years) had primary infections of osteomyelitis or orthopaedic device infections, 224 had non-prosthetic osteomyelitis, 208 had osteomyelitis related to a permanent or temporary prosthetic device, and 206 had orthopaedic device infections. The most commonly isolated pathogen was S. aureus (214 [49.1 %]; 24.8 % were MRSA). Overall, 455 (71.3 %) patients had received previous antibiotic therapy. Patients underwent surgical interventions, including tissue (225 [35.3 %]) and bone (196 [30.7 %]) debridement, as part of their treatment. Clinical success rates were 82.7 % and 81.7 % in S. aureus and coagulase-negative staphylococcal infections. Adverse events (AEs) and serious AEs assessed as possibly related to daptomycin were observed in 6.7 % and 1.9 % of patients, respectively. Daptomycin was discontinued by 5.5 % of patients due to AEs and 10 (1.6 %) deaths were reported. In conclusion, daptomycin was effective and safe in patients with osteomyelitis or orthopaedic device infections. © 2015, The Author(s). | en |
dc.language.iso | en | en |
dc.source | European Journal of Clinical Microbiology and Infectious Diseases | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84954390629&doi=10.1007%2fs10096-015-2515-6&partnerID=40&md5=e95c7dba3c859a980c97c48eb91d2813 | |
dc.subject | carbapenem derivative | en |
dc.subject | creatine kinase | en |
dc.subject | daptomycin | en |
dc.subject | glycopeptide | en |
dc.subject | penicillin derivative | en |
dc.subject | quinoline derived antiinfective agent | en |
dc.subject | antiinfective agent | en |
dc.subject | daptomycin | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | antibiotic therapy | en |
dc.subject | Article | en |
dc.subject | bactericidal activity | en |
dc.subject | bacterium isolate | en |
dc.subject | child | en |
dc.subject | coagulase negative Staphylococcus | en |
dc.subject | concentration response | en |
dc.subject | debridement | en |
dc.subject | device infection | en |
dc.subject | drug efficacy | en |
dc.subject | drug megadose | en |
dc.subject | drug safety | en |
dc.subject | drug treatment failure | en |
dc.subject | drug withdrawal | en |
dc.subject | female | en |
dc.subject | human | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | methicillin resistant Staphylococcus aureus | en |
dc.subject | methicillin susceptible Staphylococcus aureus | en |
dc.subject | multicenter study | en |
dc.subject | myalgia | en |
dc.subject | myositis | en |
dc.subject | nonhuman | en |
dc.subject | orthopedic equipment | en |
dc.subject | orthopedic prosthesis | en |
dc.subject | osteomyelitis | en |
dc.subject | priority journal | en |
dc.subject | prosthesis infection | en |
dc.subject | register | en |
dc.subject | retrospective study | en |
dc.subject | rhabdomyolysis | en |
dc.subject | side effect | en |
dc.subject | treatment outcome | en |
dc.subject | adolescent | en |
dc.subject | bacterium | en |
dc.subject | classification | en |
dc.subject | clinical trial | en |
dc.subject | Europe | en |
dc.subject | isolation and purification | en |
dc.subject | microbiology | en |
dc.subject | middle aged | en |
dc.subject | osteomyelitis | en |
dc.subject | Prosthesis-Related Infections | en |
dc.subject | very elderly | en |
dc.subject | young adult | en |
dc.subject | Adolescent | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Anti-Bacterial Agents | en |
dc.subject | Bacteria | en |
dc.subject | Child | en |
dc.subject | Daptomycin | en |
dc.subject | Debridement | en |
dc.subject | Europe | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Osteomyelitis | en |
dc.subject | Prosthesis-Related Infections | en |
dc.subject | Retrospective Studies | en |
dc.subject | Treatment Outcome | en |
dc.subject | Young Adult | en |
dc.subject | Springer Verlag | en |
dc.title | Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |